Prior view was $17.00-$17.50. FY19 consensus $17.43. Increases full year expected individual Medicare Advantage membership growth to 415,000 to 440,000 members, representing approximately 14% growth in 2019.
Wednesday, May 1, 2019
Alkermes downgraded to Neutral from Buy at Citi
Citi analyst Liav Abraham downgraded to Neutral from Buy and lowered her price target for the shares to $33.
Idexx Laboratories sees FY19 EPS $4.76-$4.88, consensus $4.73
Sees FY19 revenue $2.39B-$2.43B, consensus $2.42B.
CVS Health raises FY19 adjusted EPS view to $6.75-$6.90 from $6.68-$6.88
Consensus $6.77. Confirms cash flow from operations guidance range of $9.8B-$10.3B
CVS Health reports Q1 Retail/LTC revenues up 3.3%
Retail/LTC segment revenues increased 3.3% for the three months ended March 31, 2019 compared to the prior year. The increase was primarily driven by increased prescription volume and brand name drug price inflation, partially offset by continued reimbursement pressure and the impact of generic drug introductions. Front store revenues represent approximately 22.7% of total Retail/LTC segment revenues. Front store revenues increased in the three months ended March 31, 2019 compared to the prior year primarily driven by increases in health product sales. Total prescription volume grew 5.5%, on a 30-day equivalent basis, for the three months ended March 31, 2019 compared to the prior year. The growth was driven mainly by the continued adoption of patient care programs, collaborations with PBMs and the company’s preferred status in a number of Medicare Part D networks.
Subscribe to:
Posts (Atom)